ACADIA Pharmaceuticals Inc
ACAD
Company Profile
Business description
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Contact
12830 El Camino Real
Suite 400
San DiegoCA92130
USAT: +1 858 558-2871
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
620
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,689.70 | 37.00 | 0.43% |
| CAC 40 | 7,770.95 | 37.45 | 0.48% |
| DAX 40 | 21,042.00 | 51.69 | 0.25% |
| Dow JONES (US) | 44,025.81 | 537.98 | 1.24% |
| FTSE 100 | 8,548.29 | 27.75 | 0.33% |
| HKSE | 19,987.61 | 118.94 | -0.59% |
| NASDAQ | 19,756.78 | 126.58 | 0.64% |
| Nikkei 225 | 39,595.63 | 567.65 | 1.45% |
| NZX 50 Index | 13,074.20 | 21.30 | 0.16% |
| S&P 500 | 6,049.24 | 52.58 | 0.88% |
| S&P/ASX 200 | 8,438.60 | 36.20 | 0.43% |
| SSE Composite Index | 3,229.77 | 12.85 | -0.40% |